A decade-long journey has come to an end for Stealth BioTherapeutics and the Barth syndrome community with the first-ever ...
Bluebird bio has re-emerged after a private equity buyout as Genetix Biotherapeutics, marking a return to its roots and a new ...
The House Committee on Energy and Commerce has cleared proposed legislation that could bring back the FDA’s rare pediatric ...
BMO Capital Markets analysts said the first day of the CDC vaccine advisory committee meeting Thursday had anti-vaccine ...
After a tension-packed two days that saw recommended changes to the MMRV vaccine schedule and COVID-19 vaccine access, as ...
This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck ...
Both BMS and Novo Nordisk have, in recent months, announced steep layoffs as they strive to cut back on costs.
Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...
DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental ...
In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time ...
The sub-analysis, presented at the European Association for the Study of Diabetes congress, showed improved safety data to ...
The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback